High transduction efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex vivo gene therapy.
We recently reported the existence of fetal mesenchymal stem cells in first trimester fetal blood. Here we demonstrate that fetal mesenchymal stem cells from as early as eight weeks of gestation can be retrovirally transduced with 99% efficiency without selection. Circulating fetal mesenchymal stem cells are known to readily expand and differentiate into multiple tissue types both in vitro and in vivo, and might be suitable vehicles for prenatal gene delivery. With advances in early fetal blood sampling techniques, we suggest that genetic disorders causing irreversible damage before birth could be treated in utero in the late first/early second trimester by genetically manipulated autologous fetal stem cells.
Institute of Reproductive and Developmental Biology, Imperial College Faculty of Medicine, Hammersmith Campus, London, UK.
Cesare
C
Campagnoli
Ilaria
I
Bellantuono
Sailesh
S
Kumar
Leslie J
LJ
Fairbairn
Irene
I
Roberts
Nicholas M
NM
Fisk
D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D005333:Fetus / Q000166:cytology*; D005434:Flow Cytometry; D015316:Genetic Therapy; D006801:Humans; D008648:Mesoderm / Q000166:cytology*; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D013234:Stem Cells / Q000166:cytology*; D014161:Transduction, Genetic / Q000379:methods